# Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism

Study · id `cardio:ct-nct01848171` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01848171](<https://clinicaltrials.gov/study/NCT01848171>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01848171

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 700 participants.

## Technical summary

Registry record NCT01848171. Randomized; no masking; primary purpose treatment. Start 2013-07 (registry gives no type); primary completion 2023-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 700 participants (planned count; ClinicalTrials.gov record NCT01848171, source copy `cardio:ctgov-nct01848171-2023-01-18`, retrieved 2026-10-31)
- Start date: 2013-07 (registry gives no type) (ClinicalTrials.gov record NCT01848171, source copy `cardio:ctgov-nct01848171-2023-01-18`, retrieved 2026-10-31)
- Primary completion: 2023-07 (anticipated) (ClinicalTrials.gov record NCT01848171, source copy `cardio:ctgov-nct01848171-2023-01-18`, retrieved 2026-10-31)
- Completion: 2023-07 (anticipated) (ClinicalTrials.gov record NCT01848171, source copy `cardio:ctgov-nct01848171-2023-01-18`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT01848171, source copy `cardio:ctgov-nct01848171-2023-01-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01848171-2023-01-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism
- Condition: Hypothyroidism
- Condition: Thyroid Diseases
- Condition: Endocrine System Diseases
- Intervention (Drug): L-thyroxine
- Lead sponsor: Shandong Provincial Hospital
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Shandong Provincial Hospital (`cardio:org-shandong-provincial-hospital`)

## Provenance

Content hash: d0ffc1ed6a4aa131b73ab8d729d6861c9d6b3d3369238b65518744d73e93e404
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
